Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001031052 | SCV001194358 | likely pathogenic | Granulomatous disease, chronic, X-linked | 2019-04-12 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 13 of the CYBB gene. The 5' boundary is likely confined to intron 12 The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. This variant has not been reported in the literature in individuals with CYBB-related conditions. This variant disrupts the C-terminus of the CYBB protein. Other variant(s) that disrupt this region (p.Lys548*, p.Gln549*, p.Gly560*) have been observed in individuals with CYBB-related conditions (PMID: 20729109, 11162142). This suggests that this may be a clinically significant region of the protein. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |